Selected research
Industry Research
Peptide Vaccine for Tumor Industry Research Report 2026
Market perspective
The global Peptide Vaccine for Tumor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Peptide Vaccine for Tumor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Peptide Vaccine for Tumor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Peptide Vaccine for Tumor include AmbioPharm, Ultimovacs, Sellas Life Sciences, OncoPep, Marker Therapeutics, Inc., Immatics, Anergis, Almac and ACT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Peptide Vaccine for Tumor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide Vaccine for Tumor Market by Company
AmbioPharm
Ultimovacs
Sellas Life Sciences
OncoPep
Marker Therapeutics, Inc.
Immatics
Anergis
Almac
ACT
Peptide Vaccine for Tumor Segment by Type
Recombinant Polypeptide Vaccine
Synthetic Polypeptide Vaccines
Others
Peptide Vaccine for Tumor Segment by Application
Infectious Disease Prevention
Cancer Immunotherapy
Others
Peptide Vaccine for Tumor Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Vaccine for Tumor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Vaccine for Tumor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Vaccine for Tumor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Peptide Vaccine for Tumor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Peptide Vaccine for Tumor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Peptide Vaccine for Tumor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Polypeptide Vaccine
- Synthetic Polypeptide Vaccines
- Others
Applications
- Infectious Disease Prevention
- Cancer Immunotherapy
- Others
Companies covered
- AmbioPharm
- Ultimovacs
- Sellas Life Sciences
- OncoPep
- Marker Therapeutics, Inc.
- Immatics
- Anergis
- Almac
- ACT
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Peptide Vaccine for Tumor Market Size (2021-2032)
- 2.2.2 Global Peptide Vaccine for Tumor Sales (2021-2032)
- 2.2.3 Global Peptide Vaccine for Tumor Market Average Price (2021-2032)
- 2.3 Peptide Vaccine for Tumor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Recombinant Polypeptide Vaccine
- 2.3.3 Synthetic Polypeptide Vaccines
- 2.3.4 Others
- 2.4 Peptide Vaccine for Tumor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infectious Disease Prevention
- 2.4.3 Cancer Immunotherapy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Peptide Vaccine for Tumor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Peptide Vaccine for Tumor Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Peptide Vaccine for Tumor Revenue of Manufacturers (2021-2026)
- 3.4 Global Peptide Vaccine for Tumor Average Price by Manufacturers (2021-2026)
- 3.5 Global Peptide Vaccine for Tumor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Peptide Vaccine for Tumor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Peptide Vaccine for Tumor, Product Type & Application
- 3.8 Global Manufacturers of Peptide Vaccine for Tumor, Established Date
- 3.9 Global Peptide Vaccine for Tumor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AmbioPharm
- 4.1.1 AmbioPharm Company Information
- 4.1.2 AmbioPharm Business Overview
- 4.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AmbioPharm Peptide Vaccine for Tumor Product Portfolio
- 4.1.5 AmbioPharm Recent Developments
- 4.2 Ultimovacs
- 4.2.1 Ultimovacs Company Information
- 4.2.2 Ultimovacs Business Overview
- 4.2.3 Ultimovacs Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Ultimovacs Peptide Vaccine for Tumor Product Portfolio
- 4.2.5 Ultimovacs Recent Developments
- 4.3 Sellas Life Sciences
- 4.3.1 Sellas Life Sciences Company Information
- 4.3.2 Sellas Life Sciences Business Overview
- 4.3.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio
- 4.3.5 Sellas Life Sciences Recent Developments
- 4.4 OncoPep
- 4.4.1 OncoPep Company Information
- 4.4.2 OncoPep Business Overview
- 4.4.3 OncoPep Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 OncoPep Peptide Vaccine for Tumor Product Portfolio
- 4.4.5 OncoPep Recent Developments
- 4.5 Marker Therapeutics, Inc.
- 4.5.1 Marker Therapeutics, Inc. Company Information
- 4.5.2 Marker Therapeutics, Inc. Business Overview
- 4.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio
- 4.5.5 Marker Therapeutics, Inc. Recent Developments
- 4.6 Immatics
- 4.6.1 Immatics Company Information
- 4.6.2 Immatics Business Overview
- 4.6.3 Immatics Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Immatics Peptide Vaccine for Tumor Product Portfolio
- 4.6.5 Immatics Recent Developments
- 4.7 Anergis
- 4.7.1 Anergis Company Information
- 4.7.2 Anergis Business Overview
- 4.7.3 Anergis Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Anergis Peptide Vaccine for Tumor Product Portfolio
- 4.7.5 Anergis Recent Developments
- 4.8 Almac
- 4.8.1 Almac Company Information
- 4.8.2 Almac Business Overview
- 4.8.3 Almac Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Almac Peptide Vaccine for Tumor Product Portfolio
- 4.8.5 Almac Recent Developments
- 4.9 ACT
- 4.9.1 ACT Company Information
- 4.9.2 ACT Business Overview
- 4.9.3 ACT Peptide Vaccine for Tumor Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 ACT Peptide Vaccine for Tumor Product Portfolio
- 4.9.5 ACT Recent Developments
5 Global Peptide Vaccine for Tumor Market Scenario by Region
- 5.1 Global Peptide Vaccine for Tumor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Peptide Vaccine for Tumor Sales by Region: 2021-2032
- 5.2.1 Global Peptide Vaccine for Tumor Sales by Region: 2021-2026
- 5.2.2 Global Peptide Vaccine for Tumor Sales by Region: 2027-2032
- 5.3 Global Peptide Vaccine for Tumor Revenue by Region: 2021-2032
- 5.3.1 Global Peptide Vaccine for Tumor Revenue by Region: 2021-2026
- 5.3.2 Global Peptide Vaccine for Tumor Revenue by Region: 2027-2032
- 5.4 North America Peptide Vaccine for Tumor Market Facts & Figures by Country
- 5.4.1 North America Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Peptide Vaccine for Tumor Sales by Country (2021-2032)
- 5.4.3 North America Peptide Vaccine for Tumor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Peptide Vaccine for Tumor Market Facts & Figures by Country
- 5.5.1 Europe Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Peptide Vaccine for Tumor Sales by Country (2021-2032)
- 5.5.3 Europe Peptide Vaccine for Tumor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Peptide Vaccine for Tumor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Peptide Vaccine for Tumor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Peptide Vaccine for Tumor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Peptide Vaccine for Tumor Market Facts & Figures by Country
- 5.7.1 South America Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Peptide Vaccine for Tumor Sales by Country (2021-2032)
- 5.7.3 South America Peptide Vaccine for Tumor Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Peptide Vaccine for Tumor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Peptide Vaccine for Tumor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Peptide Vaccine for Tumor Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Peptide Vaccine for Tumor Sales by Type (2021-2032)
- 6.1.1 Global Peptide Vaccine for Tumor Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2032)
- 6.2 Global Peptide Vaccine for Tumor Revenue by Type (2021-2032)
- 6.2.1 Global Peptide Vaccine for Tumor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2032)
- 6.3 Global Peptide Vaccine for Tumor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Peptide Vaccine for Tumor Sales by Application (2021-2032)
- 7.1.1 Global Peptide Vaccine for Tumor Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Peptide Vaccine for Tumor Sales Market Share by Application (2021-2032)
- 7.2 Global Peptide Vaccine for Tumor Revenue by Application (2021-2032)
- 7.2.1 Global Peptide Vaccine for Tumor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021-2032)
- 7.3 Global Peptide Vaccine for Tumor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Peptide Vaccine for Tumor Value Chain Analysis
- 8.1.1 Peptide Vaccine for Tumor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Peptide Vaccine for Tumor Production Mode & Process
- 8.2 Peptide Vaccine for Tumor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Peptide Vaccine for Tumor Distributors
- 8.2.3 Peptide Vaccine for Tumor Customers
9 Global Peptide Vaccine for Tumor Analyzing Market Dynamics
- 9.1 Peptide Vaccine for Tumor Industry Trends
- 9.2 Peptide Vaccine for Tumor Industry Drivers
- 9.3 Peptide Vaccine for Tumor Industry Opportunities and Challenges
- 9.4 Peptide Vaccine for Tumor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst